Oncolytics Biotech Files April 2024 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Apr 12, 2024 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateApr 12, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: foreign-private-issuer, sec-filing, routine-report

Related Tickers: ONCY

TL;DR

ONCOLYTICS BIOTECH (ONCY) filed its April 6-K, confirming foreign private issuer status and 20-F annual report filing.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on April 12, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing is for the month of April 2024 and indicates they file annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech Inc.'s status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.

What is Oncolytics Biotech Inc.'s primary business sector?

Oncolytics Biotech Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.

Does Oncolytics Biotech Inc. file annual reports under Form 20-F or 40-F?

Oncolytics Biotech Inc. indicated it files annual reports under Form 20-F.

Where is Oncolytics Biotech Inc. headquartered?

Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada.

What is the filing date of this specific Form 6-K?

This Form 6-K was filed on April 12, 2024.

Filing Stats: 338 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2024-04-12 11:03:38

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) Date April 12, 2024 By s Kirk Look Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing